Pulmonary artery (PA) relaxation in response to vasodilators is significantly attenuated in models of hypoxia-induced pulmo-nary hypertension (HPH). The activity of phosphodiesterases (PDE) which hydrolyze vasodilatory second messengers may be increased by HPH, which thereby contributes to attenuated vasodilatory responses. The purpose of this study was to de-termine the effect of PDE inhibition on agonist-induced relax-ation of PA from normal rats and rats with HPH (FIO2, 0.1 for 14 days). Isolated PA rings were suspended in baths containing Krebs-Henseliet salt solution and contracted with U46619 in the presence or absence of a PDE3 (milrinone) or PDE4 (rolip-ram) inhibitor. Isoproterenol and forskolin induced concentra-tion-dependent rel...
Phosphodiesterases (PDEs) modulate the cellular proliferation involved in the pathophysiology of pul...
Relaxant responses to six vasodilator drugs, with different mechanisms of action, were examined on n...
1. The novel phosphodiesterase (PDE) inhibitor SCA40 (6-bromo-8(methylamino)imidazo[1,2-a]pyrazine-2...
Treatment of pulmonary hypertension has not yet been established and effective drug therapies are re...
Chronic treatment of rats (to induce pulmonary hypertension, PHT) for 14 days increased cGMP-inhibit...
Phosphodiesterase type-5 (PDE-5) inhibitors are novel and important options for the treatment of pul...
Phosphodiesterase (PDE) activity was determined in pulmonary arteries removed from control and chron...
Background—Phosphodiesterase type 5 (PDE5) is a novel therapeutic target for the treatment of pulmon...
Several adenosine 3',5'-cyclic monophosphate (cAMP)-hydrolyzing phosphodiesterase isozymes are prese...
1. Chronic hypoxic treatment of rats (to induce pulmonary hypertension, PHT) for 14 days increased c...
BACKGROUND: Pulmonary hypertension (PH) is a life-threatening disorder characterized by increased pu...
The pathology of pulmonary arterial hypertension (PAH) is characterized by vascular vasoconstriction...
Copyright © 2012 Edibe Karasu-Minareci et al. This is an open access article distributed under the C...
BKCa channels regulate pulmonary arterial pressure, and protein kinase C (PKC) inhibits BKCa channel...
Background: Hypoxia represents both an outcome of cardiopulmonary diseases and a trigger for severe ...
Phosphodiesterases (PDEs) modulate the cellular proliferation involved in the pathophysiology of pul...
Relaxant responses to six vasodilator drugs, with different mechanisms of action, were examined on n...
1. The novel phosphodiesterase (PDE) inhibitor SCA40 (6-bromo-8(methylamino)imidazo[1,2-a]pyrazine-2...
Treatment of pulmonary hypertension has not yet been established and effective drug therapies are re...
Chronic treatment of rats (to induce pulmonary hypertension, PHT) for 14 days increased cGMP-inhibit...
Phosphodiesterase type-5 (PDE-5) inhibitors are novel and important options for the treatment of pul...
Phosphodiesterase (PDE) activity was determined in pulmonary arteries removed from control and chron...
Background—Phosphodiesterase type 5 (PDE5) is a novel therapeutic target for the treatment of pulmon...
Several adenosine 3',5'-cyclic monophosphate (cAMP)-hydrolyzing phosphodiesterase isozymes are prese...
1. Chronic hypoxic treatment of rats (to induce pulmonary hypertension, PHT) for 14 days increased c...
BACKGROUND: Pulmonary hypertension (PH) is a life-threatening disorder characterized by increased pu...
The pathology of pulmonary arterial hypertension (PAH) is characterized by vascular vasoconstriction...
Copyright © 2012 Edibe Karasu-Minareci et al. This is an open access article distributed under the C...
BKCa channels regulate pulmonary arterial pressure, and protein kinase C (PKC) inhibits BKCa channel...
Background: Hypoxia represents both an outcome of cardiopulmonary diseases and a trigger for severe ...
Phosphodiesterases (PDEs) modulate the cellular proliferation involved in the pathophysiology of pul...
Relaxant responses to six vasodilator drugs, with different mechanisms of action, were examined on n...
1. The novel phosphodiesterase (PDE) inhibitor SCA40 (6-bromo-8(methylamino)imidazo[1,2-a]pyrazine-2...